A Phase 3 interventional study of Adalimumab and placebo in Plaque Psoriasis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 16 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-19.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.
Among the 48 studies testing adalimumab in Psoriasis, this one is the 8th largest by enrollment, is one of 4 that started in 2012, is one of 26 in phase 3, and was the 23rd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
Mabscale, LLC · Sites in Russian Federation
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ages 4–17
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 27 · Phase 4 11
First in 2003; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 425 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 148 across the 48 interventional studies. Of the 41 that completed or were terminated, 27 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 48 have an industry lead sponsor. The 10 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
79 studies in Psoriasis by AbbVie: 2 open now, 6 under way, 1 of them phase 3. Of 71 finished, 42 (59%) have results posted.
Among the 79 studies in Psoriasis by AbbVie, this one is the 10th largest by enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2012, is one of 31 in phase 3, and was the 26th registered.
AbbVie’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 48 studies testing adalimumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
A study to evaluate the safety and efficacy of adalimumab in Chinese subjects with moderate to severe plaque psoriasis.
The purpose of this study is to evaluate the safety and efficacy of adalimumab and to determine how well it works in the treatment of adults with moderate to severe plaque psoriasis in the Chinese population. Psoriasis is a chronic immunologic disease characterized by marked inflammation and thickening of the epidermis that result in thick, scaly plaques involving the skin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adalimumab 40 mg every other week (eow)
Biological: Adalimumab
placebo
Biological: placebo
adalimumab eow
Also known as: ABT-D2E7, Humira
placebo
Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 12
The percentage of participants with a greater than or equal to 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score at Week 12. PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.
Time frame: Week 12
Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response [Period A]
The percentage of participants with a greater than or equal to 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI), other than Week 12. PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.
Time frame: Weeks 3 and 7
Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response [Period B]
The percentage of participants with a greater than or equal to 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI). PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.
Time frame: Weeks 16, 19, and 24
Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score [Period A]
Psoriasis Area and Severity Index (PASI), is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.
Time frame: Baseline to Week 12
Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score [Period B]
PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.
Time frame: Baseline to Week 24
Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 50%, 90%, or 100% Reduction (PASI 50/90/100) Response [Period A]
The percentage of participants with a greater than or equal to 50%, 90%, or 100% reduction (improvement) in Psoriasis Area and Severity Index (PASI 50/90/100). PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.
Time frame: Weeks 3, 7, and 12
Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 50%, 90%, or 100% Reduction (PASI 50/90/100) Response [Period B]
The percentage of participants with a greater than or equal to 50%, 90%, or 100% reduction (improvement) in Psoriasis Area and Severity Index (PASI 50/90/100). PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.
Time frame: Weeks 16, 19, and 24
Percentage of Participants With a Physician's Global Assessment (PGA) of "Clear" [Period A]
The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'
Time frame: Baseline and Weeks 3, 7, and 12
Percentage of Participants With a Physician's Global Assessment (PGA) of "Clear" [Period B]
The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'
Time frame: Weeks 16, 19, and 24
Percentage of Participants With a Physician's Global Assessment (PGA) of "Clear" or "Minimal" [Period A]
The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'
Time frame: Baseline and Weeks 3, 7, and 12
Percentage of Participants With a Physician's Global Assessment (PGA) of "Clear" or "Minimal" [Period B]
The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'
Time frame: Weeks 16, 19, and 24
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of "0" [Period A]
The DLQI measures how much a subject's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.
Time frame: Baseline, Week 3, and Week 12
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of "0" [Period B]
The DLQI measures how much a participant's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.
Time frame: Week 16 and Week 24
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of "0 or 1" [Period A]
The DLQI measures how much a subject's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.
Time frame: Baseline, Week 3, and Week 12
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of "0 or 1" [Period B]
The DLQI measures how much a participant's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.
Time frame: Week 16 and Week 24
Change From Baseline in the Short Form 36 (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) [Period A]
Short Form-36 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: physical component summary (PCS) and mental component summary (MCS). The SF-36 consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, bodily pain, and general health perception. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have choices per item. Summations of item scores of the same subscale give the subscale scores, which were transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. PCS and MCS scores were constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score. The difference from baseline to week 12 in SF-36 PCS and MCS was calculated.
Time frame: Baseline to Week 12
Change From Baseline in the Short Form 36 (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) [Period B]
Short Form-36 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: physical component summary (PCS) and mental component summary (MCS). The SF-36 consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, bodily pain, and general health perception. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have choices per item. Summations of item scores of the same subscale give the subscale scores, which were transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. PCS and MCS scores were constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score. The difference from baseline to week 12 in SF-36 PCS and MCS was calculated.
Time frame: Baseline to Week 24
| Milestone | Placebo | Adalimumab Eow |
|---|---|---|
| Started | 87 | 338 |
| Completed | 85 | 333 |
| Not completed | 2 | 5 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Other | 0 | 1 |
| Milestone | Placebo | Adalimumab Eow |
|---|---|---|
| Started | 85 | 333 |
| Completed | 84 | 320 |
| Not completed | 1 | 13 |
| Withdrew: Adverse event | 0 | 7 |
| Withdrew: Withdrawal by subject | 1 | 5 |
| Withdrew: Lost to follow-up | 0 | 1 |
The percentage of participants with a greater than or equal to 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI) score at Week 12. PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.
| percentage of participants | Placebo | Adalimumab Eow |
|---|---|---|
| Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 12 | 11.5 | 77.8 |
The percentage of participants with a greater than or equal to 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI), other than Week 12. PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.
| percentage of participants | Placebo | Adalimumab Eow |
|---|---|---|
| Week 3 | 0 | 9.8 |
| Week 7 | 2.3 | 45.3 |
The percentage of participants with a greater than or equal to 75% reduction (improvement) in Psoriasis Area and Severity Index (PASI). PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.
| percentage of participants | Placebo/Adalimumab Eow | Adalimumab Eow/Adalimumab Eow |
|---|---|---|
| Week 16 | 51.8 | 87.4 |
| Week 19 | 80.0 | 87.1 |
| Week 24 | 90.6 | 87.7 |
Psoriasis Area and Severity Index (PASI), is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.
| Percent change | Placebo | Adalimumab Eow |
|---|---|---|
| Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score [Period A] | -20.44 ± 3.049 | -82.20 ± 1.548 |
PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.
| percent change | Placebo/Adalimumab Eow | Adalimumab Eow/Adalimumab Eow |
|---|---|---|
| Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score [Period B] | -91.39 ± 14.423 | -91.07 ± 19.028 |
The percentage of participants with a greater than or equal to 50%, 90%, or 100% reduction (improvement) in Psoriasis Area and Severity Index (PASI 50/90/100). PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.
| percentage of participants | Placebo | Adalimumab Eow |
|---|---|---|
| PASI 50 [Week 3] | 1.1 | 31.7 |
| PASI 90 [Week 3] | 0 | 2.7 |
| PASI 100 [Week 3] | 0 | 0 |
| PASI 50 [Week 7] | 11.5 | 77.2 |
| PASI 90 [Week 7] | 0 | 23.4 |
| PASI 100 [Week 7] | 0 | 3.8 |
| PASI 50 [Week 12] | 23.0 | 88.8 |
| PASI 90 [Week 12] | 3.4 | 55.6 |
| PASI 100 [Week 12] | 1.1 | 13.3 |
The percentage of participants with a greater than or equal to 50%, 90%, or 100% reduction (improvement) in Psoriasis Area and Severity Index (PASI 50/90/100). PASI is a composite measure of the level of erythema (redness of the skin), induration (hardening of the skin), and desquamation (peeling of the skin) on 4 sites (head, upper extremities, trunk, and lower extremities), each of which are rated on a 5-point scale from 0 (no symptoms) to 4 (very marked). The possible range for PASI score is 0 to 72, with the highest score representing complete erythroderma of the severest possible degree; a decrease in score indicates improvement.
| percentage of participants | Placebo/Adalimumab Eow | Adalimumab Eow/Adalimumab Eow |
|---|---|---|
| PASI 50 [Week 16] | 71.8 | 93.4 |
| PASI 90 [Week 16] | 28.2 | 70.0 |
| PASI 100 [Week 16] | 8.2 | 20.4 |
| PASI 50 [Week 19] | 92.9 | 94.3 |
| PASI 90 [Week 19] | 56.5 | 74.2 |
| PASI 100 [Week 19] | 22.4 | 28.8 |
| PASI 50 [Week 24] | 94.1 | 91.9 |
| PASI 90 [Week 24] | 75.3 | 76.3 |
| PASI 100 [Week 24] | 34.1 | 35.7 |
The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'
| percentage of participants | Placebo | Adalimumab Eow |
|---|---|---|
| Baseline | 0 | 0 |
| Week 3 | 0 | 0.6 |
| Week 7 | 0 | 12.1 |
| Week 12 | 1.1 | 25.7 |
The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'
| percentage of participants | Placebo/Adalimumab Eow | Adalimumab Eow/Adalimumab Eow |
|---|---|---|
| Week 16 | 14.1 | 39.3 |
| Week 19 | 29.4 | 42.9 |
| Week 24 | 41.2 | 45.6 |
The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'
| percentage of participants | Placebo | Adalimumab Eow |
|---|---|---|
| Baseline | 0 | 0 |
| Week 3 | 0 | 20.1 |
| Week 7 | 4.6 | 57.4 |
| Week 12 | 14.9 | 80.5 |
The Physician's Global Assessment (PGA) is a 6-point scale used to measure the severity of disease at the time of the physician's evaluation of the participant ranging from 'clear' (meaning no signs of plaque) to 'severe.'
| percentage of participants | Placebo/Adalimumab Eow | Adalimumab Eow/Adalimumab Eow |
|---|---|---|
| Week 16 | 61.2 | 85.6 |
| Week 19 | 84.7 | 84.4 |
| Week 24 | 89.4 | 83.8 |
The DLQI measures how much a subject's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.
| percentage of participants | Placebo | Adalimumab Eow |
|---|---|---|
| Baseline | 0 | 0.9 |
| Week 3 | 1.1 | 3.3 |
| Week 12 | 0 | 13.0 |
The DLQI measures how much a participant's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.
| percentage of participants | Placebo/Adalimumab Eow | Adalimumab Eow/Adalimumab Eow |
|---|---|---|
| Week 16 | 12.9 | 15.0 |
| Week 24 | 23.5 | 19.5 |
The DLQI measures how much a subject's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.
| percentage of participants | Placebo | Adalimumab Eow |
|---|---|---|
| Baseline | 1.1 | 2.4 |
| Week 3 | 3.4 | 9.2 |
| Week 12 | 10.3 | 28.4 |
The DLQI measures how much a participant's skin problem affected their life over the last week. The possible range for DLQI was 0 to 30, with a higher score indicating a more impaired quality of life; a decrease in score indicates improvement.
| percentage of participants | Placebo/Adalimumab Eow | Adalimumab Eow/Adalimumab Eow |
|---|---|---|
| Week 16 | 27.1 | 30.0 |
| Week 24 | 44.7 | 37.8 |
Short Form-36 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: physical component summary (PCS) and mental component summary (MCS). The SF-36 consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, bodily pain, and general health perception. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have choices per item. Summations of item scores of the same subscale give the subscale scores, which were transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. PCS and MCS scores were constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score. The difference from baseline to week 12 in SF-36 PCS and MCS was calculated.
| scores on a scale | Placebo | Adalimumab Eow |
|---|---|---|
| Physical Component Summary | 1.13 ± 0.665 | 4.22 ± 0.332 |
| Mental Component Summary | 1.91 ± 0.913 | 7.02 ± 0.456 |
Short Form-36 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: physical component summary (PCS) and mental component summary (MCS). The SF-36 consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, bodily pain, and general health perception. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have choices per item. Summations of item scores of the same subscale give the subscale scores, which were transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. PCS and MCS scores were constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score. The difference from baseline to week 12 in SF-36 PCS and MCS was calculated.
| scores on a scale | Placebo/Adalimumab Eow | Adalimumab Eow/Adalimumab Eow |
|---|---|---|
| Physical Component Summary | 4.20 ± 8.351 | 4.73 ± 8.260 |
| Mental Component Summary | 5.74 ± 12.661 | 7.76 ± 11.652 |
Collected over Baseline up to 70 days after last dose (week 24).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double-blind Placebo | — | 3/87 (3.4%) | 14/87 (16.1%) |
| Double-blind Adalimumab Eow | — | 4/338 (1.2%) | 64/338 (18.9%) |
| Any Adalimumab | — | 15/423 (3.5%) | 137/423 (32.4%) |
| Event | Double-blind Placebo | Double-blind Adalimumab Eow | Any Adalimumab |
|---|---|---|---|
| RETINAL DETACHMENTEye disorders | 1/87 | 0/338 | 0/423 |
| PSORIATIC ARTHROPATHYMusculoskeletal and connective tissue disorders | 1/87 | 0/338 | 0/423 |
| PSORIASISSkin and subcutaneous tissue disorders | 1/87 | 0/338 | 0/423 |
| LUNG INFECTIONInfections and infestations | 0/87 | 0/338 | 2/423 |
| PNEUMONIAInfections and infestations | 0/87 | 0/338 | 2/423 |
| MYOCARDIAL INFARCTIONCardiac disorders | 0/87 | 1/338 | 1/423 |
| LUMBAR VERTEBRAL FRACTUREInjury, poisoning and procedural complications | 0/87 | 1/338 | 1/423 |
| CEREBRAL INFARCTIONNervous system disorders | 0/87 | 1/338 | 1/423 |
| HAEMATURIARenal and urinary disorders | 0/87 | 1/338 | 1/423 |
| HYPERTENSIONVascular disorders | 0/87 | 1/338 | 1/423 |
| Event | Double-blind Placebo | Double-blind Adalimumab Eow | Any Adalimumab |
|---|---|---|---|
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 6/87 | 34/338 | 68/423 |
| NASOPHARYNGITISInfections and infestations | 5/87 | 13/338 | 38/423 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 1/87 | 14/338 | 30/423 |
| COUGHRespiratory, thoracic and mediastinal disorders | 4/87 | 11/338 | 27/423 |
| Age, Continuous(years) | Placebo | Adalimumab Eow | Total |
|---|---|---|---|
| Mean | 43.8 ± 12.45 | 43.1 ± 11.91 | 43.2 ± 12.01 |
| Sex: Female, Male(Participants) | Placebo | Adalimumab Eow | Total |
|---|---|---|---|
| Female | 29 | 84 | 113 |
| Male | 58 | 254 | 312 |
| Duration of Psoriasis(years) | Placebo | Adalimumab Eow | Total |
|---|---|---|---|
| Mean | 15.79 ± 10.309 | 14.84 ± 10.114 | 15.03 ± 10.149 |
| Body Surface Area with Psoriasis(Percentage of Body Surface Area) | Placebo | Adalimumab Eow | Total |
|---|---|---|---|
| Mean | 39.30 ± 22.502 | 42.62 ± 21.748 | 41.94 ± 21.918 |
| Psoriasis Area and Severity Index(units on a scale) | Placebo | Adalimumab Eow | Total |
|---|---|---|---|
| Mean | 25.60 ± 10.978 | 28.19 ± 11.999 | 27.66 ± 11.831 |
| Physician's Global Assessment of Psoriasis(participants) | Placebo | Adalimumab Eow | Total |
|---|---|---|---|
| Clear | 0 | 0 | 0 |
| Minimal | 0 | 0 | 0 |
| Mild | 0 | 0 | 0 |
| Moderate | 57 | 214 | 271 |
| Marked | 28 | 110 | 138 |
| Severe | 2 | 14 | 16 |
The record gives a start of Aug 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
AbbVie (prior sponsor, Abbott) →